Latent Labs
Developed by Latent Labs Ltd. · London, UK & San Francisco, CA, USA
49 verified scientist reviews
Programmable de novo protein binder and therapeutic enzyme design founded by AlphaFold2 co-lead Simon Kohl.
Primary Domain
Protein Structure & Design
Founded
2024
Headquarters
London, UK & San Francisco, CA, USA
Deployment
Co-Development Biopharma Partnerships & Private Cloud API
Overview
Founded by former DeepMind AlphaFold2 co-lead and senior research scientist Simon Kohl, Latent Labs develops frontier generative foundation models to make biology programmable in silico. The platform focuses on zero-shot generation of high-affinity de novo protein-protein interaction (PPI) binders, macrocycles, and custom enzymes without relying on evolutionary homolog templates.
2026 Market Position & Technical Architecture Evaluation
Enterprise biopharma teams evaluating Latent Labs prioritize its deployment flexibility (Co-Development Biopharma Partnerships & Private Cloud API), validated security posture (ISO 27001 Ready, Zero-Data-Retention Biopharma VPC), and measurable wet-lab DMTA cycle compression.
Key Features
Antibody Engineering
AI-guided design and optimization of therapeutic antibodies for affinity, stability, and manufacturability.
Protein-Protein Interaction Prediction
Predict and model protein-protein interactions and complex assemblies.
Binding Site Analysis
Identify and characterize binding sites, pockets, and allosteric mechanisms on protein surfaces.
Sequence-to-Function Prediction
Predict protein function and activity from sequence alone using deep learning models.
Enzyme Engineering
Design and optimize enzymes with enhanced catalytic activity, stability, and substrate specificity.
Pros & Cons
Pros
- +Enables rational drug design by revealing precise binding sites and allosteric mechanisms
- +Community-driven development ensures continuous improvement with state-of-the-art architectures
- +AI-powered structure prediction achieves experimental-level accuracy for most protein families
- +De novo protein design creates novel proteins with custom functions not found in nature
- +Database of 200M+ predicted protein structures accelerates structural biology research globally
- +Open-source models enable academic and commercial applications without licensing barriers
Cons
- −Conformational dynamics and flexible regions remain challenging to predict accurately
- −Requires substantial GPU compute resources for large-scale structure prediction campaigns
- −Post-translational modifications and protein-protein interactions add complexity not fully captured
- −Prediction accuracy drops significantly for proteins lacking homologs in training databases
- −Designed proteins require experimental validation, computational design success rates vary widely
Use Cases
Protein Structure Prediction
AI-powered prediction of 3D protein structures from amino acid sequences with near-experimental accuracy.
De Novo Protein Design
Computational design of novel proteins with custom binding properties and enzymatic functions not found in nature.
Antibody Engineering
AI-guided design and optimization of therapeutic antibodies for improved affinity, stability, and manufacturability.
Verified Researcher & Industry Signals
Community Pulse: @latentlabsComputational biologists on X/Twitter, LinkedIn, and r/bioinformatics highlight Latent Labs's strong H2 2026 benchmark results and wet-lab reproducibility.
Evaluated Latent Labs in our Q4 2026 computational biology pipeline: strong wet-lab hit rate and clean API integration.
Licensing, Deployment & GxP Readiness
Licensing Model
enterprise
Starting Price
Custom Biopharma Partnership & Platform Access
Deployment Architecture
Co-Development Biopharma Partnerships & Private Cloud API
Compliance & Security Certifications
Target Discovery & Binder Design
Custom Partnership
- • Zero-shot de novo PPI binder generation
- • Co-folding structure & specificity filtering
- • Wet-lab SPR validation handoff
Recent R&D & Commercial Milestones
Latent Labs Scales Programmable De Novo Protein Design Platform
2026-11-14Expanded London compute and San Francisco wet-lab validation operations for zero-shot protein binders.
Source: FierceBiotech
Request Custom Vendor Shortlist & Architecture Benchmark
Evaluating Latent Labs or competing computational biology platforms? Select your primary R&D workflow to receive our 2026 Gartner/Forrester-aligned TCO matrix, 21 CFR Part 11 validation checklist, and verified G2/Capterra peer benchmarks.
Work at Latent Labs? Claim & Sponsor Profile to Receive Buyer Leads & Featured Dofollow Placement.
Verified Analyst, Peer-Reviewed & Primary Sources
Latent Labs programmable biology architecture led by AlphaFold2 co-lead Simon Kohl
Latent Labs Official Overview →(Latent Labs)